APA (7th ed.) Citation

Arseni, L., Sigismondo, G., Yazdanparast, H., Hermansen, J. U., Mack, N., Ohl, S., . . . Seiffert, M. (2025). Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL. Nature Communications, 16, . https://doi.org/10.1038/s41467-025-56318-7

Chicago Style (17th ed.) Citation

Arseni, Lavinia, et al. "Longitudinal Omics Data and Preclinical Treatment Suggest the Proteasome Inhibitor Carfilzomib as Therapy for Ibrutinib-resistant CLL." Nature Communications 16 (2025). https://doi.org/10.1038/s41467-025-56318-7.

MLA (9th ed.) Citation

Arseni, Lavinia, et al. "Longitudinal Omics Data and Preclinical Treatment Suggest the Proteasome Inhibitor Carfilzomib as Therapy for Ibrutinib-resistant CLL." Nature Communications, vol. 16, 2025, https://doi.org/10.1038/s41467-025-56318-7.